Evidence map›Paper›PMID 40584407›Full record

ReviewMedComm2025

Transforming Growth Factor-β Pathway: Biological Functions and Therapeutic Targets.

Reham Hassan Mekky, Mohammed E Abo-El Fetoh, Safaa A Faheem, Abdullah F Radwan, Mariam H Fawzy, Aya M Mustafa, Mohamed A Said, Daniela Calina, Javad Sharifi-Rad, William C Cho

Abstract readReview
In one paragraph

Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Reham Hassan MekkyDepartment of Pharmacognosy Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt.ORCID https://orcid.org/0000-0001-5613-5666
Mohammed E Abo-El FetohDepartment of Pharmacology and Toxicology Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt.ORCID https://orcid.org/0000-0002-7937-0084
Safaa A FaheemDepartment of Pharmacology and Toxicology Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt.
Abdullah F RadwanDepartment of Biochemistry and Molecular Biology Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt.
Mariam H FawzyDepartment of Pharmacology and Toxicology Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt.
Aya M MustafaDepartment of Pharmacology and Toxicology Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt.
Mohamed A SaidDepartment of Pharmaceutical Chemistry Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt.
Daniela CalinaDepartment of Clinical Pharmacy University of Medicine and Pharmacy of Craiova Craiova Romania.
Javad Sharifi-RadUniversidad Espíritu Santo Samborondón Ecuador.ORCID https://orcid.org/0000-0002-7301-8151
William C ChoDepartment of Clinical Oncology Queen Elizabeth Hospital Kowloon Hong Kong SAR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer progression is often driven by aberrant cell growth and genetic mutations, leading to metastasis. The transforming growth factor-beta (TGF-β) pathway, a key regulator of cellular growth and differentiation, exhibits dual roles in cancer by initially acting as a tumor suppressor and later promoting tumor progression and metastasis. Natural compounds, recognized for their diverse bioactivities and low toxicity, have shown potential in targeting cancer-related pathways, including TGF-β signaling. This review examines the therapeutic potential of natural products in modulating TGF-β signaling and their anticancer effects across various cancer types. We evaluated relevant preclinical and clinical studies assessing the impact of natural products on TGF-β modulation and cancer progression. Natural compounds from sources such as plants impact TGF-β signaling, influencing processes like cell proliferation, apoptosis, and angiogenesis. Key compounds reviewed include ginsenosides, halofuginone, and epigallocatechin gallate, demonstrating significant anticancer activity via TGF-β pathway modulation. These findings suggest natural products may serve as complementary therapies in cancer treatment by targeting TGF-β signaling, potentially improving patient outcomes. Continued research and clinical evaluation are necessary to integrate these compounds into conventional cancer therapies, aiming to offer safer, cost-effective options that enhance quality of life.

Indexed as

angiogenesisapoptosiscancer progressionnatural compoundsTGF‐β pathwaytherapeutic modulation

Identifiers

PMID40584407
PMCPMC12205216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.